Leah Cann's Strong Oncology and Financial Background a Plus for Growing Company
NEW CANAAN, CT and SYDNEY, AUSTRALIA -- (Marketwire) -- 03/19/09 -- Marshall Edwards, Inc.
(NASDAQ: MSHL) is pleased to announce the appointment of Leah Cann to the
Board of Directors of the Company.
Ms. Cann is an independent research analyst in Newport, Rhode Island. She
began her career as a research scientist with Memtec Corporation and moved
to Wall Street in 1992, where she was a research analyst with CIBC
Oppenheimer for nearly nine years. Ms. Cann was a heath care analyst for
the Boston-based asset manager, Cadence Capital, and later the senior
biotechnology analyst for Wachovia Securities. Twice recognized as an
All-Star analyst by the Wall Street Journal, she is the founder of Leah
Rush Cann Research and Consulting, LLC, a Newport, Rhode Island-based
cancer research and consulting organization. She is also Founder and
Chairman of the Board of Hope Funds for Cancer Research, and a member of
the New York Academy of Sciences.
Ms. Cann received a BA in Art History and Chemistry and an MBA from Stetson
University. She was a post-baccalaureate at the College of William and
Mary and a post-graduate at Columbia University. She has been a trustee
and member of several committees of International House in New York City
for more than 10 years.
Marshall Edwards' Board Chairman, Professor Bryan Williams, welcomed Ms.
Cann to the Board. She has been appointed chair of the Company Audit
Committee.
The Company also announces that Mr. William D. Rueckert has resigned from
the Marshall Edwards' Board, and has accepted a position on the Board of
the Company's 72 per cent shareholder, Novogen Limited. Chairman Williams,
on behalf of the board and shareholders, thanked Mr. Rueckert for his
skillful and effective contributions as a Marshall Edwards' director.
About Marshall Edwards, Inc. and Novogen Limited
Marshall Edwards is a specialist oncology company focused on the clinical
development of novel anti-cancer therapeutics. These derive from a
flavonoid technology platform that has generated a number of novel
compounds characterized by broad ranging activity in laboratory testing
against a range of cancer targets with few side effects. The ability of
these compounds to inhibit the production of pro-survival proteins within
the cancer cell suggests that they may possess a unique combination of
efficacy and safety. Marshall Edwards has licensed rights from Novogen
Limited (ASX: NRT) (NASDAQ: NVGN) to bring oncology drugs including
phenoxodiol and triphendiol (NV-196) to market globally. Marshall Edwards
is majority owned by Novogen, an Australian biotechnology company that is
specializing in the development of therapeutics based on a flavonoid
technology platform.
